- Report
- February 2026
- 100 Pages
Global, Africa, Middle East Global, Africa, Middle East
From €4411EUR$4,799USD£3,760GBP
- Report
- February 2026
- 100 Pages
Global, India
From €4411EUR$4,799USD£3,760GBP
- Report
- January 2026
- 150 Pages
Global
From €5469EUR$5,950USD£4,662GBP
- Report
- September 2026
- 190 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- October 2026
- 193 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- July 2026
- 150 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- April 2026
- 301 Pages
Global
From €2298EUR$2,500USD£1,959GBP
- Report
- February 2026
- 148 Pages
Global
From €3676EUR$3,999USD£3,133GBP
- Report
- April 2026
- 116 Pages
Global
From €4366EUR$4,750USD£3,721GBP
- Report
- December 2025
- 150 Pages
Global
From €4458EUR$4,850USD£3,800GBP
- Report
- November 2025
- 160 Pages
Global
From €2905EUR$3,160USD£2,476GBP
€3631EUR$3,950USD£3,095GBP
- Training
- September 2027
- 2 Days
Global
€1577EUR$1,776USD£1,299GBP
€1820EUR$2,050USD£1,499GBP
- Training
- March 2027
- 2 Days
Global
€1577EUR$1,776USD£1,299GBP
€1820EUR$2,050USD£1,499GBP
- Report
- April 2026
- 143 Pages
Europe
From €3676EUR$3,999USD£3,133GBP
- Report
- September 2026
Global
From €4411EUR$4,799USD£3,760GBP
- Report
- September 2026
- 183 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- September 2026
- 195 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- September 2026
- 185 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more